Good morning :)
$
₹
Xeris Pharmaceuticals Inc

Xeris Pharmaceuticals Inc

XERS

NASDAQ
Asset Logo

Xeris Pharmaceuticals Inc

XERS

NASDAQ
$10.461.12% (+0.11)
$
₹
$10.461.12% (+0.11)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Small Cap

With a market cap of $1.9B the stock is ranked 2232

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

107.67
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.1
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-5.12%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 7 analysts reports

Buy
6 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+22.92%

Earnings Growth

-1284.62%

Rev. Growth

+32.91%

See Detailed Forecast

Company Profile

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
46.00
46.00
1Y Return
56.59%
56.59%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.05
41.05
1Y Return
48.81%
48.81%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
149.85
149.85
1Y Return
79.29%
79.29%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
30.82
30.82
1Y Return
31.97%
31.97%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.39
26.39
1Y Return
11.26%
11.26%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 22.92% growth, versus a trailing 3-year CAGR of 78.15%.

2026
Current$10.46Baseline
Analyst Target - 1 year
Target$12.86+22.92%

All values in $

202220232024202520262027$4.43$7.67$10.91Target+22.92%
2026
Current$10.46Baseline
Analyst Target - 1 year
Target$12.86+22.92%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 32.91% growth, versus a trailing 3-year CAGR of 38.33%.

2025
Current$291.84Baseline
Forecast for Dec 2026
High$390.9+33.94%
Average$387.90+32.91%
Low$385.7+32.16%

All values in $ Million

20212022202320242025202649.59110.24163.91203.07291.84Low+32.16%Average+32.91%High+33.94%
2025
Current$291.84Baseline
Forecast for Dec 2026
High$390.9+33.94%
Average$387.90+32.91%
Low$385.7+32.16%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.01Baseline
Forecast for Dec 2026
High$-0.03-361.54%
Average$-0.09-1284.62%
Low$-0.14-2053.85%

All values in $

202120222023202420252026-1.52-0.7-0.45-0.33-0.01Low-2053.85%Average-1284.62%High-361.54%
2025
Current$-0.01Baseline
Forecast for Dec 2026
High$-0.03-361.54%
Average$-0.09-1284.62%
Low$-0.14-2053.85%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

74.3
0.6
85.8
11
83.1
2.2
92.1
-31.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue40.6348.0654.2660.0960.1171.5374.3885.8083.1292.1
Net Income-18.98-15-15.73-5.11-9.22-1.920.6211.082.23-31.10
Net Profit Margin-46.70%-31.21%-29.00%-8.50%-15.33%-2.69%0.83%12.91%2.68%-33.76%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Xeris Pharmaceuticals Inc -107.67-
Eli Lilly and Company46.0031.351.35
Johnson & Johnson41.058.063.07
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare XERS with any stock or ETF
Compare XERS with any stock or ETF
Comparing from
XERS
LLY
JNJ
Loading...

Frequently asked questions

  1. Xeris Pharmaceuticals Inc (XERS) share price today is $10.46 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $10.70 and a day low of $10.16.

  2. Xeris Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol XERS.

  3. Xeris Pharmaceuticals Inc's market capitalization is $1.85B as of November 5, 2026 at 2:29 AM IST.

  4. Xeris Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Xeris Pharmaceuticals Inc's price-to-book (P/B) ratio is 107.67 as of November 4, 2026.

  6. Yes, You can buy Xeris Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Xeris Pharmaceuticals Inc shares in three steps: 1. Search Xeris Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Xeris Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Xeris Pharmaceuticals Inc (XERS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.9554 shares at the current price of $10.46.

Loading...